Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEDIATRIC LTA KIT vs LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.
Lidocaine is a sodium channel blocker that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby producing local anesthesia. Dextrose 5% provides caloric support.
Local dermal anesthesia for minor procedures (e.g., laceration repair, skin biopsy) in pediatric patients
Treatment of acute atrial fibrillation (sodium channel blocker effect),Local anesthesia (when used as a local anesthetic preparation; however, this formulation is typically used for IV administration and not for infiltration),Off-label: ventricular arrhythmias, status epilepticus (IV lidocaine)
Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.
Intravenous administration: Initial dose of 1-1.5 mg/kg (up to 300 mg total) given at a rate not exceeding 50 mg/min. Followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min) for arrhythmia management.
2-3 hours (terminal) in children with normal renal function; prolonged in renal impairment
Terminal elimination half-life: 1.5–2 hours (prolonged to 2–3 hours in hepatic impairment; unchanged in renal impairment).
No dosage adjustment required. Lidocaine and tetracaine are extensively hepatically metabolized; renal excretion of metabolites is minor. Use caution in severe renal impairment due to potential accumulation of metabolites.
No specific dose adjustment required for lidocaine; however, use with caution in severe renal impairment (GFR < 10 m L/min) due to potential accumulation of metabolites.
None.
No known teratogenic risk in first trimester; lidocaine and epinephrine are not associated with major congenital malformations at standard doses. Second and third trimester: no fetal harm reported; high doses may cause fetal bradycardia due to systemic absorption.
Lidocaine crosses the placenta. First trimester: No well-controlled studies; animal studies show no evidence of fetal harm. Second trimester: No specific risks identified; used for epidural anesthesia without increased malformations. Third trimester: IV lidocaine may cause fetal bradycardia; uterine artery vasoconstriction reported with high doses. Dextrose 5%: No teratogenic risk.
This kit contains lidocaine, tetracaine, and epinephrine for topical anesthesia. Apply to intact skin only; avoid mucous membranes. Maximum combined dose of lidocaine and tetracaine should not exceed 20 mg/kg or 1000 mg total. Use with caution in patients with hepatic impairment, arrhythmias, or concurrent use of class III antiarrhythmics. Epinephrine may cause local ischemia; avoid use on digits, ears, nose, or penis. Monitor ECG for QT prolongation.
Lidocaine hydrochloride 0.2% in D5W is primarily used as a continuous IV infusion for acute ventricular arrhythmias, especially post-MI. Monitor for CNS toxicity (tinnitus, perioral numbness) and cardiac toxicity (QRS widening, hypotension). Reduce dose in heart failure, hepatic impairment, and elderly. Therapeutic level: 1.5-5 mcg/m L. Avoid in second-degree or third-degree AV block without pacemaker.
No interactions on record
No interactions on record
Common clinical questions about PEDIATRIC LTA KIT vs LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PEDIATRIC LTA KIT is a Local Anesthetic that works by PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.. LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER is a Local Anesthetic / Antiarrhythmic (Class Ib) that works by Lidocaine is a sodium channel blocker that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby producing local anesthesia. Dextrose 5% provides caloric support.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEDIATRIC LTA KIT and LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEDIATRIC LTA KIT is: Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.. The standard adult dose of LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous administration: Initial dose of 1-1.5 mg/kg (up to 300 mg total) given at a rate not exceeding 50 mg/min. Followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min) for arrhythmia management.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEDIATRIC LTA KIT and LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEDIATRIC LTA KIT is classified as Category C. No known teratogenic risk in first trimester; lidocaine and epinephrine are not associated with major congenital malformations at standard doses. Second and third trimester: no fet. LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category A/B. Lidocaine crosses the placenta. First trimester: No well-controlled studies; animal studies show no evidence of fetal harm. Second trimester: No specific risks identified; used for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Lidocaine: primarily hepatic via CYP3A4 and CYP1A2 to active metabolites (MEGX, GX). Tetracaine: primarily hydrolyzed by plasma esterases (pseudocholinesterase) to para-aminobenzoic acid (PABA). Epinephrine: metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Lidocaine is primarily metabolized in the liver by CYP1A2 and CYP3A4 to monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Dextrose is metabolized via glycolysis.
Renal (95% as unchanged drug), fecal (5%)
Renal excretion of unchanged drug and metabolites: 10% unchanged, 90% as metabolites (primarily 4-hydroxy-2,6-xylidine and glycylxylidide). Less than 1% biliary/fecal.
20-30% bound to albumin
70% bound primarily to alpha1-acid glycoprotein (AAG) and albumin; binding saturable and increased in inflammatory states.
0.5-0.7 L/kg, indicating distribution into total body water
Vd: 1.1–1.7 L/kg (central compartment Vc: 0.5 L/kg; distributes rapidly to well-perfused tissues).
Oral: 60-75% (first-pass effect); Intramuscular: 80-90%
Oral: 35% (extensive first-pass metabolism); Subcutaneous: 100% (complete absorption); Rectal: 30–50% (variable). IV: 100%.
Lidocaine and tetracaine are hepatically metabolized. In severe hepatic impairment (Child-Pugh C), risk of systemic toxicity increased; consider avoiding or using with extreme caution. No specific dose adjustment defined.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce loading dose by 50% and infusion rate by 50%. Child-Pugh Class C: Reduce loading dose by 75% and infusion rate by 75%.
Approved for pediatric patients weighing ≥10 kg. Apply one patch to intact skin for 20-30 minutes; maximum 3 patches. Do not apply to broken skin or mucous membranes. Avoid in infants <3 months due to risk of methemoglobinemia.
Weight-based dosing: Loading dose: 1-1.5 mg/kg IV (max 100 mg). Infusion: 20-50 mcg/kg/min IV. For neonates: Loading dose 0.5-1 mg/kg, infusion 10-30 mcg/kg/min.
No specific dose adjustment; elderly may have impaired hepatic or renal function. Use with caution due to thinner skin and increased systemic absorption risk. Monitor for local and systemic adverse effects. Maximum 3 patches per session.
Reduce initial dose by 50% and monitor closely due to decreased hepatic clearance and increased risk of toxicity. Typical initial loading dose: 0.5-0.75 mg/kg IV.
None
No specific food interactions. However, avoid excessive caffeine or stimulants as epinephrine may increase risk of cardiovascular side effects. No dietary restrictions.
No specific food interactions. However, as the solution contains dextrose, monitor blood glucose in diabetic patients. Grapefruit juice may theoretically increase lidocaine levels (CYP3A4 inhibition), but clinical significance is unclear.
Lidocaine excreted into breast milk in low concentrations (M/P ratio ~0.4). Epinephrine has minimal milk excretion. Considered compatible with breastfeeding; monitor infant for local anesthetic toxicity signs (e.g., drowsiness, apnea).
Lidocaine is excreted into breast milk in low amounts; M/P ratio approximately 0.4. American Academy of Pediatrics considers compatible with breastfeeding. Dextrose 5% does not affect lactation.
No dose adjustment required for standard infiltration; pharmacokinetic changes in pregnancy (increased plasma volume and cardiac output) may slightly reduce peak concentrations but no empirical dose change needed.
No dose adjustment required for epidural or local administration. For IV antiarrhythmic use: pregnancy may increase volume of distribution, but loading dose unchanged; clearance may be reduced, so infusion rates should be titrated to effect with careful monitoring. Dextrose 5% dose based on glucose requirements.
Apply only to intact skin; do not use on cuts, scrapes, or inside mouth/nose.,Wash hands after application and avoid touching eyes.,Keep out of reach of children; accidental ingestion can cause serious side effects.,Do not use with other numbing medications without consulting doctor.,Seek immediate medical help if you experience difficulty breathing, swelling, or severe allergic reaction.,Inform your doctor if you have heart disease, liver problems, or are pregnant/breastfeeding.
This medication is given into a vein to treat irregular heartbeats.,Report any ringing in ears, numbness around mouth, dizziness, or confusion immediately.,You may experience drowsiness or blurred vision; avoid driving until effects are known.,This solution contains dextrose; inform your doctor if you have diabetes.,Do not stop or adjust the infusion rate on your own.